Paulson & CO. Inc. Invests $58.58 Million in Horizon Pharma PLC (HZNP) Stock

Paulson & CO. Inc. acquired a new stake in Horizon Pharma PLC (NASDAQ:HZNP) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 4,935,500 shares of the biopharmaceutical company’s stock, valued at approximately $58,584,000. Horizon Pharma PLC makes up about 0.8% of Paulson & CO. Inc.’s investment portfolio, making the stock its 29th largest position. Paulson & CO. Inc. owned 3.02% of Horizon Pharma PLC at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. BlackRock Inc. increased its stake in shares of Horizon Pharma PLC by 1.8% in the 2nd quarter. BlackRock Inc. now owns 13,500,226 shares of the biopharmaceutical company’s stock worth $160,247,000 after acquiring an additional 239,014 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Horizon Pharma PLC by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 12,982,718 shares of the biopharmaceutical company’s stock worth $154,105,000 after acquiring an additional 233,443 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Horizon Pharma PLC by 119.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 6,265,608 shares of the biopharmaceutical company’s stock worth $74,373,000 after acquiring an additional 3,409,411 shares during the last quarter. State Street Corp increased its stake in shares of Horizon Pharma PLC by 12.0% in the 2nd quarter. State Street Corp now owns 4,906,307 shares of the biopharmaceutical company’s stock worth $58,241,000 after acquiring an additional 524,187 shares during the last quarter. Finally, Janus Capital Management LLC increased its stake in shares of Horizon Pharma PLC by 19.4% in the 1st quarter. Janus Capital Management LLC now owns 4,409,717 shares of the biopharmaceutical company’s stock worth $65,173,000 after acquiring an additional 717,643 shares during the last quarter. Institutional investors own 82.32% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/10/17/paulson-co-inc-invests-58-58-million-in-horizon-pharma-plc-hznp-stock.html.

Shares of Horizon Pharma PLC (HZNP) traded up 0.552% during mid-day trading on Tuesday, hitting $13.665. The company had a trading volume of 515,095 shares. Horizon Pharma PLC has a 12 month low of $9.45 and a 12 month high of $21.98. The company’s market cap is $2.23 billion. The firm has a 50-day moving average of $13.09 and a 200-day moving average of $12.69.

Horizon Pharma PLC (NASDAQ:HZNP) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.12 by $0.29. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The firm had revenue of $289.51 million for the quarter, compared to the consensus estimate of $237.01 million. During the same period in the prior year, the business posted $0.56 earnings per share. The firm’s revenue for the quarter was up 12.5% compared to the same quarter last year. On average, analysts expect that Horizon Pharma PLC will post $1.07 EPS for the current year.

A number of brokerages have issued reports on HZNP. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $17.00 target price (up from $13.00) on shares of Horizon Pharma PLC in a research note on Wednesday, August 9th. Zacks Investment Research raised Horizon Pharma PLC from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. BMO Capital Markets reaffirmed a “buy” rating and issued a $17.00 target price on shares of Horizon Pharma PLC in a research note on Friday, July 28th. Piper Jaffray Companies set a $18.00 target price on Horizon Pharma PLC and gave the stock a “buy” rating in a research note on Monday, August 7th. Finally, BidaskClub downgraded Horizon Pharma PLC from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. One analyst has rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the company. Horizon Pharma PLC has a consensus rating of “Buy” and a consensus target price of $18.00.

Horizon Pharma PLC Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Institutional Ownership by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply